Last July, Biogen (BIIB) executives unveiled a new, more aggressive business development plan. Cash thrown off by the biotech’s maturing but still very profitable multiple sclerosis franchise would be redeployed to license or acquire new neuroscience assets.
Biogen was eyeing prospective deals up to $10 billion to $12 billion in size, CEO Michel Vounatsos told investors.
About the Author Reprints
